- Home
- CRVS vs ABEO Comparison
CRVS vs ABEO Comparison
Compare CRVS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ABEO
- Stock Information
- Founded
- CRVS 2014
- ABEO 1974
- Country
- CRVS United States
- ABEO United States
- Employees
- CRVS N/A
- ABEO N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- ABEO Health Care
- Exchange
- CRVS Nasdaq
- ABEO Nasdaq
- Market Cap
- CRVS 305.4M
- ABEO 256.9M
- IPO Year
- CRVS 2016
- ABEO 1980
- Fundamental
- Price
- CRVS $4.11
- ABEO $5.69
- Analyst Decision
- CRVS Strong Buy
- ABEO Strong Buy
- Analyst Count
- CRVS 4
- ABEO 6
- Target Price
- CRVS $15.00
- ABEO $18.00
- AVG Volume (30 Days)
- CRVS 1.2M
- ABEO 1.1M
- Earning Date
- CRVS 08-05-2025
- ABEO 08-11-2025
- Dividend Yield
- CRVS N/A
- ABEO N/A
- EPS Growth
- CRVS N/A
- ABEO N/A
- EPS
- CRVS N/A
- ABEO N/A
- Revenue
- CRVS N/A
- ABEO N/A
- Revenue This Year
- CRVS N/A
- ABEO N/A
- Revenue Next Year
- CRVS N/A
- ABEO $323.51
- P/E Ratio
- CRVS N/A
- ABEO N/A
- Revenue Growth
- CRVS N/A
- ABEO N/A
- 52 Week Low
- CRVS $1.78
- ABEO $3.93
- 52 Week High
- CRVS $10.00
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- CRVS 53.94
- ABEO 47.54
- Support Level
- CRVS $3.79
- ABEO $5.68
- Resistance Level
- CRVS $4.31
- ABEO $5.93
- Average True Range (ATR)
- CRVS 0.29
- ABEO 0.26
- MACD
- CRVS 0.00
- ABEO -0.01
- Stochastic Oscillator
- CRVS 72.64
- ABEO 56.25
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.